blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2212291

EP2212291 - HETEROCYCLE PHENYL AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  10.04.2015
Database last updated on 14.11.2024
Most recent event   Tooltip15.07.2016Lapse of the patent in a contracting state
New state(s): MT		published on 17.08.2016  [2016/33]
Applicant(s)For all designated states
Merck Sharp & Dohme Corp.
126 East Lincoln Avenue
Rahway, NJ 07065-0907 / US
[2014/23]
Former [2012/33]For all designated states
Merck Sharp & Dohme Corp.
126 East Lincoln Avenue
Rahway NJ 07065-0907 / US
Former [2010/31]For all designated states
Merck Sharp & Dohme Corp.
126 East Lincoln Avenue
Rahway, NJ 07065 / US
Inventor(s)01 / BARROW, James, C.
126 East Lincoln Avenue
Rahway New Jersey 07065-0907 / US
02 / COLEMAN, Paul, J.
126 East Lincoln Avenue
Rahway New Jersey 07065-0907 / US
03 / REGER, Thomas, S.
126 East Lincoln Avenue
Rahway New Jersey 07065-0907 / US
04 / SCHLEGEL, Kelly-ann, S.
126 East Lincoln Avenue
Rahway New Jersey 07065-0907 / US
05 / SHU, Youheng
126 East Lincoln Avenue
Rahway New Jersey 07065-0907 / US
06 / YANG, Zhi-Qiang
126 East Lincoln Avenue
Rahway New Jersey 07065-0907 / US
 [2010/31]
Representative(s)Buchan, Gavin MacNicol
Merck Sharp & Dohme Limited
European Patent Department
Hertford Road
Hoddesdon
Hertfordshire EN11 9BU / GB
[N/P]
Former [2014/23]Buchan, Gavin MacNicol
Merck Sharp & Dohme Limited European Patent Department Hertford Road Hoddesdon
Hertfordshire EN11 9BU / GB
Former [2010/31]Buchan, Gavin MacNicol
Merck Sharp & Dohme Limited European Patent Department Hertford Road Hoddesdon
Hertfordshire EN11 9BU / GB
Application number, filing date08843270.323.10.2008
[2010/31]
WO2008US12039
Priority number, dateUS20070000156P24.10.2007         Original published format: US 156 P
US20080072568P01.04.2008         Original published format: US 72568 P
[2014/03]
Former [2010/31]US2007000015624.10.2007
US2008007256801.04.2008
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2009054984
Date:30.04.2009
Language:EN
[2009/18]
Type: A1 Application with search report 
No.:EP2212291
Date:04.08.2010
Language:EN
The application published by WIPO in one of the EPO official languages on 30.04.2009 takes the place of the publication of the European patent application.
[2010/31]
Type: B1 Patent specification 
No.:EP2212291
Date:04.06.2014
Language:EN
[2014/23]
Search report(s)International search report - published on:EP30.04.2009
ClassificationIPC:C07D213/65, C07D401/12, C07D405/12, C07D413/12, C07D417/12, C07D487/04, A61K31/44, A61P25/08
[2010/31]
CPC:
C07D401/12 (EP,US); A61P25/00 (EP); A61P25/04 (EP);
A61P25/08 (EP); A61P25/16 (EP); A61P25/18 (EP);
A61P25/20 (EP); A61P25/22 (EP); A61P25/24 (EP);
A61P25/28 (EP); A61P25/30 (EP); A61P29/00 (EP);
A61P31/10 (EP); A61P35/00 (EP); A61P43/00 (EP);
A61P9/08 (EP); A61P9/12 (EP); C07D213/65 (EP,US);
C07D405/12 (EP,US); C07D413/12 (EP,US); C07D417/12 (EP,US);
C07D487/04 (EP,US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2010/31]
TitleGerman:HETEROZYKLISCHE CALCIUMKANAL-ANTAGONISTEN VOM TYP PHENYLAMID T[2010/31]
English:HETEROCYCLE PHENYL AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS[2010/31]
French:ANTAGONISTES DE CANAUX CALCIQUES DE TYPE T À BASE DE PHÉNYLE AMIDE HÉTÉROCYCLIQUE[2010/31]
Entry into regional phase25.05.2010National basic fee paid 
25.05.2010Designation fee(s) paid 
25.05.2010Examination fee paid 
Examination procedure23.04.2010Amendment by applicant (claims and/or description)
25.05.2010Examination requested  [2010/31]
05.07.2011Despatch of a communication from the examining division (Time limit: M04)
10.11.2011Reply to a communication from the examining division
17.05.2013Despatch of a communication from the examining division (Time limit: M04)
27.09.2013Reply to a communication from the examining division
18.12.2013Communication of intention to grant the patent
16.04.2014Fee for grant paid
16.04.2014Fee for publishing/printing paid
16.04.2014Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  05.07.2011
Opposition(s)05.03.2015No opposition filed within time limit [2015/20]
Fees paidRenewal fee
23.09.2010Renewal fee patent year 03
10.10.2011Renewal fee patent year 04
05.10.2012Renewal fee patent year 05
07.10.2013Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU23.10.2008
AT04.06.2014
BE04.06.2014
BG04.06.2014
CY04.06.2014
CZ04.06.2014
DK04.06.2014
EE04.06.2014
ES04.06.2014
FI04.06.2014
HR04.06.2014
IT04.06.2014
LT04.06.2014
LV04.06.2014
MC04.06.2014
MT04.06.2014
NL04.06.2014
PL04.06.2014
RO04.06.2014
SE04.06.2014
SI04.06.2014
SK04.06.2014
TR04.06.2014
NO04.09.2014
GR05.09.2014
IS04.10.2014
PT06.10.2014
IE23.10.2014
LU23.10.2014
CH31.10.2014
LI31.10.2014
[2016/33]
Former [2016/32]HU23.10.2008
AT04.06.2014
BE04.06.2014
BG04.06.2014
CY04.06.2014
CZ04.06.2014
DK04.06.2014
EE04.06.2014
ES04.06.2014
FI04.06.2014
HR04.06.2014
IT04.06.2014
LT04.06.2014
LV04.06.2014
MC04.06.2014
NL04.06.2014
PL04.06.2014
RO04.06.2014
SE04.06.2014
SI04.06.2014
SK04.06.2014
TR04.06.2014
NO04.09.2014
GR05.09.2014
IS04.10.2014
PT06.10.2014
IE23.10.2014
LU23.10.2014
CH31.10.2014
LI31.10.2014
Former [2016/25]AT04.06.2014
BG04.06.2014
CY04.06.2014
CZ04.06.2014
DK04.06.2014
EE04.06.2014
ES04.06.2014
FI04.06.2014
HR04.06.2014
IT04.06.2014
LT04.06.2014
LV04.06.2014
MC04.06.2014
NL04.06.2014
PL04.06.2014
RO04.06.2014
SE04.06.2014
SI04.06.2014
SK04.06.2014
NO04.09.2014
GR05.09.2014
IS04.10.2014
PT06.10.2014
IE23.10.2014
LU23.10.2014
CH31.10.2014
LI31.10.2014
Former [2015/46]AT04.06.2014
CY04.06.2014
CZ04.06.2014
DK04.06.2014
EE04.06.2014
ES04.06.2014
FI04.06.2014
HR04.06.2014
IT04.06.2014
LT04.06.2014
LV04.06.2014
MC04.06.2014
NL04.06.2014
PL04.06.2014
RO04.06.2014
SE04.06.2014
SI04.06.2014
SK04.06.2014
NO04.09.2014
GR05.09.2014
IS04.10.2014
PT06.10.2014
IE23.10.2014
LU23.10.2014
CH31.10.2014
LI31.10.2014
Former [2015/36]AT04.06.2014
CY04.06.2014
CZ04.06.2014
DK04.06.2014
EE04.06.2014
ES04.06.2014
FI04.06.2014
HR04.06.2014
IT04.06.2014
LT04.06.2014
LV04.06.2014
MC04.06.2014
NL04.06.2014
PL04.06.2014
RO04.06.2014
SE04.06.2014
SI04.06.2014
SK04.06.2014
NO04.09.2014
GR05.09.2014
IS04.10.2014
PT06.10.2014
LU23.10.2014
CH31.10.2014
LI31.10.2014
Former [2015/33]AT04.06.2014
CY04.06.2014
CZ04.06.2014
DK04.06.2014
EE04.06.2014
ES04.06.2014
FI04.06.2014
HR04.06.2014
IT04.06.2014
LT04.06.2014
LV04.06.2014
MC04.06.2014
NL04.06.2014
PL04.06.2014
RO04.06.2014
SE04.06.2014
SK04.06.2014
NO04.09.2014
GR05.09.2014
IS04.10.2014
PT06.10.2014
LU23.10.2014
CH31.10.2014
LI31.10.2014
Former [2015/27]AT04.06.2014
CY04.06.2014
CZ04.06.2014
DK04.06.2014
EE04.06.2014
ES04.06.2014
FI04.06.2014
HR04.06.2014
IT04.06.2014
LT04.06.2014
LV04.06.2014
MC04.06.2014
NL04.06.2014
PL04.06.2014
RO04.06.2014
SE04.06.2014
SK04.06.2014
NO04.09.2014
GR05.09.2014
IS04.10.2014
PT06.10.2014
LU23.10.2014
Former [2015/26]AT04.06.2014
CY04.06.2014
CZ04.06.2014
DK04.06.2014
EE04.06.2014
ES04.06.2014
FI04.06.2014
HR04.06.2014
IT04.06.2014
LT04.06.2014
LV04.06.2014
NL04.06.2014
PL04.06.2014
RO04.06.2014
SE04.06.2014
SK04.06.2014
NO04.09.2014
GR05.09.2014
IS04.10.2014
PT06.10.2014
LU23.10.2014
Former [2015/22]AT04.06.2014
CY04.06.2014
CZ04.06.2014
DK04.06.2014
EE04.06.2014
ES04.06.2014
FI04.06.2014
HR04.06.2014
IT04.06.2014
LT04.06.2014
LV04.06.2014
NL04.06.2014
PL04.06.2014
RO04.06.2014
SE04.06.2014
SK04.06.2014
NO04.09.2014
GR05.09.2014
IS04.10.2014
PT06.10.2014
Former [2015/12]AT04.06.2014
CY04.06.2014
CZ04.06.2014
EE04.06.2014
ES04.06.2014
FI04.06.2014
HR04.06.2014
LT04.06.2014
LV04.06.2014
NL04.06.2014
PL04.06.2014
RO04.06.2014
SE04.06.2014
SK04.06.2014
NO04.09.2014
GR05.09.2014
IS04.10.2014
PT06.10.2014
Former [2015/11]AT04.06.2014
CY04.06.2014
CZ04.06.2014
EE04.06.2014
ES04.06.2014
FI04.06.2014
HR04.06.2014
LT04.06.2014
LV04.06.2014
PL04.06.2014
RO04.06.2014
SE04.06.2014
SK04.06.2014
NO04.09.2014
GR05.09.2014
PT06.10.2014
Former [2015/10]AT04.06.2014
CY04.06.2014
CZ04.06.2014
EE04.06.2014
ES04.06.2014
FI04.06.2014
HR04.06.2014
LT04.06.2014
LV04.06.2014
SE04.06.2014
SK04.06.2014
NO04.09.2014
GR05.09.2014
Former [2014/51]AT04.06.2014
CY04.06.2014
FI04.06.2014
HR04.06.2014
LT04.06.2014
LV04.06.2014
SE04.06.2014
NO04.09.2014
GR05.09.2014
Former [2014/50]CY04.06.2014
FI04.06.2014
HR04.06.2014
LT04.06.2014
LV04.06.2014
SE04.06.2014
NO04.09.2014
GR05.09.2014
Former [2014/49]CY04.06.2014
FI04.06.2014
LT04.06.2014
NO04.09.2014
Former [2014/48]CY04.06.2014
LT04.06.2014
Former [2014/47]CY04.06.2014
Cited inInternational search[A]WO2007002361  (MERCK & CO INC [US], et al) [A] 1-18* page 2, line 7 - line 12 *;
 [DPX]WO2007120729  (MERCK & CO INC [US], et al) [DPX] 1-18 * page 2, line 12 - line 17; examples 2,3,14,15,etc; claim 1 *;
 [PX]WO2008064157  (INCYTE CORP [US], et al) [PX] 1-7,9-12,14,15 * example 188 *;
 [X]  - REGISTRY, Chemical Abstracts Service, Columbus, Ohio, USA, (20070423), XP002513623 [X] 1-6,10-12 * Registry number 931970-35-3; Benzeneacetamide, 4-(2-methyl-3H-imidazo(4,5-b)pyridin-3-yl)-N-(2-pyridinylmethyl)-; Supplier: Aurora Fine Chemicals. *
 [X]  - REGISTRY, Chemical Abstracts Service, Columbus, Ohio, USA, (20060727), XP002513624 [X] 1-3,6,10-12 * Registry number 896376-19-5; Benzeneacetamide, 4-(1,4-dihydro-2,4-dioxo-3(2H)-quinazolinyl)-N-(2-pyridinylmethyl)-; Supplier: Aurora Fine Chemicals *
 [X]  - REGISTRY, Chemical Abstracts Service, Columbus, Ohio, USA, (20060718), XP002513625 [X] 1-6,10-12 * Registry number 894181-12-5; Benzeneacetamide, 4-(2-ethyl-3H-imidazo[4,5-b]pyridin-3-yl)-N-(2-pyridinylmethyl)-; Supplier: Aurora Fine Chemicals *
 [X]  - REGISTRY, Chemical Abstracts Service, Columbus, Ohio, USA, (20070422), XP002513626 [X] 1-3,6,10-12 * Registry number 931630-57-8; Benzeneacetamide, 4-(2-oxo-1-pyrrolidinyl)-N-(2-pyridinylmethyl)-; Supplier: Enamine *
 [X]  - REGISTRY, Chemical Abstracts Service, Columbus, Ohio, USA, (20050801), XP002513627 [X] 1,5,6,10-12 * Registry number 857861-48-4; Benzeneacetamide, 4-[[3-(phenylmethyl)-1,2,4-thiadiazol-5-yl]oxy]-N-(2-pyridinylmethyl)-; Supplier: ComGenex International Inc. *
 [X]  - REGISTRY, Chemical Abstracts Service, Columbus, Ohio, USA, (20050715), XP002513628 [X] 1,5,6,10-12 * Registry number 855509-20-5; Benzeneacetamide, 4-[[3-[(4-fluorophenyl)methyl]-1,2,4-thiadiazol-5-yl]oxy]-N-(2-pyridinylmethyl)-; Supplier: ComGenex International Inc. *
 [X]  - REGISTRY, Chemical Abstracts Service, Columbus, Ohio, USA, (20050708), XP002513629 [X] 1,5,6,10-12 * Registry number 854170-18-6; Benzeneacetamide, 4-[[3-[(3-methoxyphenyl)methyl]-1,2,4-thiadiazol-5-yl]oxy]-N-(2-pyridinylmethyl)-; Supplier: ComGenex International Inc. *
 [X]  - REGISTRY, Chemical Abstracts Service, Columbus, Ohio, USA, (20040606), XP002513630 [X] 1-3,6,10-12 * Registry number; 689763-76-6; Benzeneacetamide, 4-(1,4-dihydro-4-oxo-2-thioxo-3(2H)-quinazolinyl)-N-(2-pyridinylmethyl)-; Supplier: ChemDiv. Inc. *
by applicant   - J BIOL. CHEM., (2001), vol. 276, no. 6, pages 3999 - 4011
    - EUR J NEUROSCI, (1999), vol. 11, no. 12, pages 4171 - 8
    - CELL MOL LIFE SCI, (1999), vol. 56, no. 7-8, pages 660 - 9
    - J NEUROSCIENCE, (1994), vol. 14, page 5485
    - DRUGS FUTURE, (2005), vol. 30, no. 6, pages 573 - 580
    - EMBO J, (2005), vol. 24, pages 315 - 324
    - DRUG DISCOVERY TODAY, (2006), vol. 11, no. 5/6, pages 245 - 253
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.